Armlupeg PFS Q Code: Q5169

Drug & Product Overview

HCPCS Descriptor Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg

HCPCS Added Date July 1, 2026

Manufacturer Valorum Biologics

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About Armlupeg PFS

Armlupeg PFS is a medication aligned to the HCPCS Q Code: Q5169 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology Colony Stimulating Factor drug administered via the subcutaneous route and manufactured by Valorum Biologics.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
70748-0273-01	6 MG / 0.6 ML Armlupeg Subcutaneous Injection 6 MG/0.6ML - 1 SYRINGE in 1 CARTON (70748-273-01) / .6 mL in 1 SYRINGE	Valorum Biologics, LLC	12	$6,097.08 $508.09 / unit	$7,316.50 $609.708 / unit

Effective 4/1/26 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Armlupeg PFS Pricing & Reimbursement

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

Pegfilgrastim Biosimilar Information:

Armlupeg PFS Approval Date: November 28, 2025

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neulasta	J2506	Pegfilgrastim	351(a) Originator Product
Fulphila	Q5108	Pegfilgrastim	351(k) Biosimilar
Udenyca	Q5111	Pegfilgrastim	351(k) Biosimilar
Ziextenzo	Q5120	Pegfilgrastim	351(k) Biosimilar
Nyvepria	Q5122	Pegfilgrastim	351(k) Biosimilar
Fylnetra	Q5130	Pegfilgrastim	351(k) Biosimilar
Stimufend	Q5127	Pegfilgrastim	351(k) Biosimilar
Armlupeg	Q5169	Pegfilgrastim	351(k) Biosimilar
Ennumo	N/A	Pegfilgrastim	351(k) Biosimilar

Armlupeg PFS CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Armlupeg PFS Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Hematopoietic subsyndrome of acute radiation syndrome Patients with cancer receiving myelosuppressive chemotherapy (decrease incidence of infection/febrile neutropenia)

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there an available Armlupeg PFS billing and coding guide?

A manufacturer-published billing and coding guide for ARMLUPEG PFS was not found.

Are there any available Armlupeg patient assistance programs?

No manufacturer-published ARMLUPEG PFS patient assistance link was found.

Where can I find Armlupeg Pfs prescribing information?

ARMLUPEG PFS prescribing information can be found at the link below: Visit Here →

Where can I find Armlupeg Pfs side effect information?

Information regarding ARMLUPEG PFS's side effects can be found at MedlinePlus Visit Here →

Does billing ARMLUPEG PFS require JZ/JW wastage modifiers?

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.